<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Turk J Haematol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Turk J Haematol</journal-id>
      <journal-id journal-id-type="publisher-id">TJH</journal-id>
      <journal-title-group>
        <journal-title>Turkish Journal of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1300-7777</issn>
      <issn pub-type="epub">1308-5263</issn>
      <publisher>
        <publisher-name>Galenos Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26316486</article-id>
      <article-id pub-id-type="pmc">4451486</article-id>
      <article-id pub-id-type="doi">10.4274/tjh.2014.0021</article-id>
      <article-id pub-id-type="publisher-id">1457</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity</article-title>
        <trans-title-group xml:lang="tr">
          <trans-title>&#x130;matinib Mesilat ile &#x130;li&#x15F;kili Deri Toksisitesinde &#x130;nterl&#xF6;kin-31/33 Aks&#x131;n&#x131;n Olas&#x131; Rol&#xFC;</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Musolino</surname>
            <given-names>Caterina</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Allegra</surname>
            <given-names>Alessandro</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="COR1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mannucci</surname>
            <given-names>Carmen</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Russo</surname>
            <given-names>Sabina</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alonci</surname>
            <given-names>Andrea</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maisano</surname>
            <given-names>Valerio</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Calapai</surname>
            <given-names>Gioacchino</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gangemi</surname>
            <given-names>Sebastiano</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>
University of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, Italy
</aff>
      <aff id="A2"><label>2</label>
Azienda Ospedaliera Universitaria Policlinico &#x201C;G. Martino&#x201D;, Department of Clinical and Experimental Medicine, Operative Unit of Clinical Pharmacology, Messina, Italy
</aff>
      <aff id="A3"><label>3</label>
University of Messina Faculty of Medicine, Policlinic &#x201C;G. Martino&#x201D;, Department of Clinical and Experimental Medicine, Division of Allergy and Clinical Immunology, Messina, Italy
</aff>
      <aff id="A4"><label>4</label>
IFC CNR, Messina Unit, Institute of Clinical Physiology, Messina, Italy
</aff>
      <author-notes>
        <corresp id="COR1">* Address for Correspondence: University of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, Italy Phone: 0039 090 221 23 64 E-mail: <email>aallegra@unime.it</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <volume>32</volume>
      <issue>2</issue>
      <fpage>168</fpage>
      <lpage>171</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>3</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Turkish Journal of Hematology, Published by Galenos Publishing.&#xD;
</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent. The aim of this work was to investigate the possible contribution of interleukin (IL)-33 and IL-31, cytokines involved in disorders associated with itching, in the pathogenesis of pruritus in a patient undergoing imatinib mesylate treatment. His IL-31 and IL-33 serum levels were significantly higher than in the control group (respectively 96.6 pg/mL vs. 7.623&#xB1;7.681 pg/mL and 27.566 pg/mL vs. 6.170&#xB1;7.060 pg/mL). In light of these findings, imatinib mesylate-related symptoms of dermatologic toxicities might be related to the release of IL-31 and IL-33. In particular, it is supposable that TKi usage could cause keratinocyte injury, the release of IL-33, and the consequent interaction with its receptor on mast cells that induces the secretion of several factors capable of causing skin manifestations, including IL-31, a known pruritus-inducing cytokine. This report, to the best of our knowledge, is the first work describing the possible involvement of the IL-31/IL-33 axis in the pathogenesis of skin side effects related to imatinib mesylate treatment.</p>
      </abstract>
      <trans-abstract xml:lang="tr">
        <p>&#x130;matinib mesilat c-ABL ve BCR-ABL&#x2019;yi hedeflemek i&#xE7;in tasarlanan k&#xFC;&#xE7;&#xFC;k- molek&#xFC;l tirozin kinaz inhibit&#xF6;r&#xFC; (TK&#x130;) olup kronik miyeloid l&#xF6;semi ve gastrointestinal stromal t&#xFC;m&#xF6;r tedavisi i&#xE7;in onaylanm&#x131;&#x15F;t&#x131;r. &#x130;matinib ile ind&#xFC;klenen advers kutan&#xF6;z reaksiyonlar nadir, genellikle &#x131;l&#x131;ml&#x131; ve doz ba&#x11F;&#x131;ml&#x131;d&#x131;r. Bu &#xE7;al&#x131;&#x15F;man&#x131;n amac&#x131;, ka&#x15F;&#x131;nt&#x131; ile ili&#x15F;kili bozukluklar ile ilgili sitokinler olan interl&#xF6;kin (IL)-33 ve IL-31&#x2019;in imatinib mesilat tedavisi alan bir hastada ka&#x15F;&#x131;nt&#x131; patogenezine olas&#x131; katk&#x131;s&#x131;n&#x131; ara&#x15F;t&#x131;rmak idi. Hastan&#x131;n serum IL-31 ve IL-33 d&#xFC;zeyleri kontrol grubundan anlaml&#x131; olarak y&#xFC;ksek idi (s&#x131;ras&#x131;yla; 96,6 pg/mL vs. 7,623&#xB1;7,681 pg/mL ve 27,566 pg/mL vs. 6,170&#xB1;7,060 pg/mL). Bu bulgular &#x131;&#x15F;&#x131;&#x11F;&#x131;nda, imatinib mesilat- ile ili&#x15F;kili dermatolojik toksisiteler IL-31 ve IL-33 sal&#x131;n&#x131;m&#x131; ile ili&#x15F;kili olabilir. &#xD6;zellikle, TK&#x130; kullan&#x131;m&#x131;n&#x131;n keratinosit hasar&#x131;, IL-33 sal&#x131;n&#x131;m&#x131; ve mast h&#xFC;cre y&#xFC;zeyindeki resept&#xF6;r&#xFC; ile kar&#x15F;&#x131;l&#x131;kl&#x131; etkile&#x15F;imi sonucu, deri bulgular&#x131;na yol a&#xE7;ma yetene&#x11F;i olan, ka&#x15F;&#x131;nt&#x131;y&#x131;-ind&#xFC;kleyen bir sitokin olarak bilinen IL-31&#x2019;de i&#xE7;eren &#xE7;e&#x15F;itli fakt&#xF6;rlerin sekresyonuna sebep olabilece&#x11F;i varsay&#x131;labilir. Bu rapor, bildi&#x11F;imizce, imatinin mesilat tedavisi ile ili&#x15F;kili deri yan etkilerinin patogenezinde interl&#xF6;kin-31/33 aks&#x131;n&#x131;n olas&#x131; rol&#xFC;n&#xFC; tan&#x131;mlayan ilk &#xE7;al&#x131;&#x15F;mad&#x131;r.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Interleukin-31 (IL-31)</kwd>
        <kwd>Interleukin-33 (IL-33)</kwd>
        <kwd>Tyrosine kinase inhibitors</kwd>
        <kwd>Imatinib mesylate</kwd>
        <kwd>Chronic myeloid leukemia</kwd>
        <kwd>Pruritus</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>INTRODUCTION</title>
      <p>Imatinib mesylate is a tyrosine kinase inhibitor (TKi) approved for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors [<xref rid="ref1" ref-type="bibr">1</xref>]. Several case reports noted the occurrence of dose-limiting skin disorders during imatinib administration [<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref4" ref-type="bibr">4</xref>,<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref6" ref-type="bibr">6</xref>]. Interleukin (IL)-33 is a recently recognized cytokine that appears to drive T helper type 2 (Th2) responses [<xref rid="ref7" ref-type="bibr">7</xref>,<xref rid="ref8" ref-type="bibr">8</xref>,<xref rid="ref9" ref-type="bibr">9</xref>]. IL-33 has been linked to important diseases, including asthma, rheumatoid arthritis, ulcerative colitis, and metabolic, neurologic, and cardiovascular diseases.</p>
      <p>IL-31 is a member of the IL-6 family of cytokines, mainly expressed in pruritic disorders [<xref rid="ref10" ref-type="bibr">10</xref>]. IL-31 is a Th2 cytokine that is mainly produced by the CD45RO+ cutaneous lymphocyte antigen-positive T lymphocytes. It is involved in both innate and adaptive immunity in tissues that are in close contact with the external environment, i.e. the skin [<xref rid="ref11" ref-type="bibr">11</xref>]. Recently IL-31 has been demonstrated to be produced by human mast cells [<xref rid="ref11" ref-type="bibr">11</xref>]; in addition, monocytes, macrophages, and monocyte-derived dendritic cells produce IL-31. Moreover, epidermal keratinocytes and dermal fibroblasts show enhanced IL-31 mRNA expression upon H2O2 stimulation [<xref rid="ref10" ref-type="bibr">10</xref>]. Enhanced expression of IL-31 is associated with a number of diseases, including pruritic diseases such as atopic dermatitis, allergic contact dermatitis, prurigo nodularis, and chronic urticaria [<xref rid="ref12" ref-type="bibr">12</xref>].</p>
      <p>In a previous work we reported a significant increase of IL-31 and IL-33 serum levels in a patient with a bronchoalveolar carcinoma, who had shown previous skin rash, xerosis, and pruritus during treatment with different EGFR-TK inhibitors [<xref rid="ref13" ref-type="bibr">13</xref>]. The aim of this work was to investigate the possible contribution of IL-31 and IL-33, cytokines involved in disorders associated with itching, in the pathogenesis of pruritus in a patient undergoing imatinib mesylate treatment.</p>
    </sec>
    <sec id="s2">
      <title>CASE PRESENTATION</title>
      <p>A 73-year-old man, while being evaluated for splenomegaly, showed leukocytosis upon peripheral blood examination with low hemoglobin and normal platelet count. His past medical history included hypertension, stroke, and dyslipidemia. He had no history of drug allergy.</p>
      <p>His provisional diagnosis was CML, which was subsequently confirmed by the presence of Philadelphia (Ph) chromosome [Ph+ t (9;22) (q34;q11)] in 100% of the cells in metaphase. He was started on cytoreduction with hydroxyurea. Subsequently, he started to take imatinib mesylate at 400 mg once daily. While on therapy, he developed pruritus. Physical examination revealed erythema of the skin associated with mild exfoliation, which affected mainly the upper and lower limbs. There was no history of application of or contact with any irritant substances. Systemic antihistamines were administered. Moreover, the patient was treated with a short course of corticosteroids along with topical clobetasol propionate. Imatinib mesylate was discontinued for 2 weeks, and the patient showed some improvement. Imatinib was restarted at 100 mg once daily and was gradually built up to 300 mg once daily with reappearance of the pruritus. </p>
      <p>On further follow-up, he had achieved complete hematologic response at 6 months, but failed to achieve a cytogenetic response or a major molecular response at 12 months. His pruritus has become constant and involves his entire body. He is unable to sleep unless medicated with sedatives. The patient is still only in complete hematological response and our intent is to shift to a second-line TKi. </p>
      <p>We evaluated IL-31 and IL-33 serum levels in this patient and in 18 sex- and age-matched healthy controls. The study was conducted according to good clinical and laboratory practice rules and the principles of the Declaration of Helsinki, and it was approved by the local ethics committee. After obtaining written informed consent, blood samples were collected to determine IL-31 and IL-33 serum levels. </p>
      <p>We used a standard sandwich ELISA kit (USCN Life Science, Houston, TX, USA). The lower limit of detection was determined as suggested by the manufacturer, as follows: (mean negative control optical density) + 2 x (StDev of negative control optical density). The absorbance was measured at 450 nm. </p>
      <p>The patient&#x2019;s IL-31 and IL-33 serum levels were markedly higher than those in the control group (respectively 96.6 pg/mL vs. 7.623&#xB1;7.681 pg/mL and 27.566 pg/mL vs. 6.170&#xB1;7.060 pg/mL).</p>
    </sec>
    <sec id="s3">
      <title>DISCUSSION AND REVIEW OF THE LITERATURE</title>
      <p>Imatinib mesylate is a small-molecule TKi designed to target c-ABL and BCR-ABL, but it is also able to target KIT and the platelet-derived growth factor (PDGF) receptor.</p>
      <p>Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent [<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref15" ref-type="bibr">15</xref>], although all grades of cutaneous reactions have been reported, ranging from exfoliative dermatitis to vesicular rash and Stevens-Johnson syndrome [<xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref17" ref-type="bibr">17</xref>,<xref rid="ref18" ref-type="bibr">18</xref>,<xref rid="ref19" ref-type="bibr">19</xref>].</p>
      <p>Concerning the pathogenesis of skin reactions occurring during imatinib administration, a direct effect of the tyrosine kinase inhibition on the PDGF receptor, expressed on dermal mast cells and blood vessels, was suggested [<xref rid="ref20" ref-type="bibr">20</xref>]. </p>
      <p>The inhibition of this receptor might cause an augmentation of dermal interstitial fluid pressure with subsequent phenomena of skin edema and erythema. However, the histological evidence for an augmented number of dermal mast cells, which express a functional c-kit receptor, in cases of severe skin toxicity from imatinib mesylate seems to exclude a direct effect of the drug on mast cells themselves [<xref rid="ref21" ref-type="bibr">21</xref>,<xref rid="ref22" ref-type="bibr">22</xref>].</p>
      <p>As a result, it has also been proposed that imatinib mesylate might operate as a dose-dependent inducer of chemoattractant substances able to induce pruritus [<xref rid="ref21" ref-type="bibr">21</xref>], such as IL-33 and IL-31. </p>
      <p>IL-33 has recently been attributed to the epithelial &#x2018;alarmin&#x2019; defense system. IL-33 is liberated by the epithelial cells in several tissues and organs, including keratinocytes, immune cells, and endothelial cells [<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref23" ref-type="bibr">23</xref>]. </p>
      <p>It has been proven that IL-33 is recognized by T1/ST2 receptors on the surface of mast cells; this results in the secretion of proinflammatory factors, including IL-6, TNF-&#x3B1;, and leukotrienes. Subsequently, these signals can cause changes, including vasodilatation, increased permeability of the microvasculature, and recruitment of inflammatory cells [<xref rid="ref23" ref-type="bibr">23</xref>].</p>
      <p>The link between pruritus and IL-31 has also been confirmed by a study showing that transgenic mice models over-expressing IL-31 developed severe pruritus and an increase in mast cells [<xref rid="ref24" ref-type="bibr">24</xref>]. Moreover, it is probable that IL-31 may generate pruritus through the induction of a yet unknown keratinocyte-derived mediator, which subsequently activates unmyelinated C fibers in the skin [<xref rid="ref25" ref-type="bibr">25</xref>].</p>
      <p>It is presumable that the skin manifestations and itch caused by imatinib mesylate treatment could be related to the release of IL-31 and IL-33. It is supposable that TKi usage can cause keratinocyte injury with the release of IL-33, which in turn interacts with its receptor on mast cells, leading to the secretion of several factors capable of causing skin manifestations, including IL-31 [<xref rid="ref26" ref-type="bibr">26</xref>,<xref rid="ref27" ref-type="bibr">27</xref>].</p>
      <p>Finally, our finding of very high serum levels of IL-33 and IL-31 in a CML patient undergoing imatinib mesylate treatment compared to healthy controls has a more relevant significance in light of previous works, where we found a significant decrease of IL-33 plasma levels in patients affected by myeloproliferative disorders such as polycythemia vera and essential thrombocythemia and in subjects with other hematologic diseases [<xref rid="ref28" ref-type="bibr">28</xref>,<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref>]. For this reason, although we have no information about basal IL-31 and -33 levels in our CML patient before imatinib treatment, we think that the increase of the values of cytokines after imatinib treatment with respect to the controls is significant.</p>
      <p>In conclusion, although our report, with the description of a unique case, does not permit us to draw sure conclusions on the possible association between itch and TKi usage, further studies conducted using different TKis such as nilotinib and dasatinib will be useful to better define the role of these cytokines in these patients.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="FN1" fn-type="conflict">
        <p>
          <bold>Conflict of Interest Statement</bold>
        </p>
        <p>The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Savage</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Antman</surname>
              <given-names>KH</given-names>
            </name>
          </person-group>
          <article-title>Imatinib mesylate &#x2013; a new oral targeted therapy</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>346</volume>
          <fpage>683</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="pmid">11870247</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Brouard</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Prins</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mach-Pascual</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Saurat</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukaemia</article-title>
          <source>Dermatology</source>
          <year>2001</year>
          <volume>203</volume>
          <fpage>57</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="pmid">11549802</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Brouard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saurat</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous reactions to STI571</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>345</volume>
          <fpage>618</fpage>
          <lpage>619</lpage>
          <pub-id pub-id-type="pmid">11529225</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Drummond</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Micallef-Eynaud</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Hay</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Holyoake</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Drummond</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI571, Glivec&#xAE;)</article-title>
          <source>Br J Haematol</source>
          <year>2003</year>
          <volume>120</volume>
          <fpage>907</fpage>
          <lpage>915</lpage>
          <pub-id pub-id-type="pmid">12614229</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Breccia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carmosino</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Morano</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Latagliata</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Alimena</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib</article-title>
          <source>Eur J Haematol</source>
          <year>2005</year>
          <volume>74</volume>
          <fpage>121</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="pmid">15654902</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Valeyrie</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bastuji-Garin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Revuz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bachot</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wechsler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Berthaud</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tulliez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giraudier</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2003</year>
          <volume>48</volume>
          <fpage>201</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="pmid">12582389</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Pushparaj</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Tay</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>H&#x2019;ng</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Pitman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>McKenzie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Liew</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Melendez</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>The cytokine interleukin-33 mediates anaphylactic shock</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2009</year>
          <volume>106</volume>
          <fpage>9773</fpage>
          <lpage>9778</lpage>
          <pub-id pub-id-type="pmid">19506243</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Joshi</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Oak</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Hartigan</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Finn</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Kunkel</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Duffy</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hogaboam</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages</article-title>
          <source>BMC Immunol</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>52</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">20958987</pub-id>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Cevikbas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Steinhoff</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>IL-33: a novel danger signal system in atopic dermatitis</article-title>
          <source>J Invest Dermatol</source>
          <year>2012</year>
          <volume>132</volume>
          <fpage>1326</fpage>
          <lpage>1329</lpage>
          <pub-id pub-id-type="pmid">22499037</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Cornelissen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brans</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Czaja</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Skazik</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Marquardt</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zwadlo-Klarwasser</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bickers</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>L&#xFC;scher-Firzlaff</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>L&#xFC;scher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Baron</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells</article-title>
          <source>Br J Dermatol</source>
          <year>2011</year>
          <volume>165</volume>
          <fpage>966</fpage>
          <lpage>975</lpage>
          <pub-id pub-id-type="pmid">21711332</pub-id>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Cornelissen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>L&#xFC;scher-Firzlaff</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Baron</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>L&#xFC;scher</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Signaling by IL-31 and functional consequences</article-title>
          <source>Eur J Cell Biol</source>
          <year>2012</year>
          <volume>91</volume>
          <fpage>552</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="pmid">21982586</pub-id>
        </element-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Sonkoly</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lauerma</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Pivarcsi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Soto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kemeny</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alenius</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dieu-Nosjean</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Meller</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rieker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Steinhoff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Ruzicka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zlotnik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Homey</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>IL-31: a new link between T cells and pruritus in atopic skin inflammation</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2006</year>
          <volume>117</volume>
          <fpage>411</fpage>
          <lpage>417</lpage>
          <pub-id pub-id-type="pmid">16461142</pub-id>
        </element-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Gangemi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Franchina</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Minciullo</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Profita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zangh&#xEC;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Adamo</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>IL-33/IL-31 axis: a new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity</article-title>
          <source>J Cell Biochem</source>
          <year>2013</year>
          <volume>114</volume>
          <fpage>2673</fpage>
          <lpage>2676</lpage>
          <pub-id pub-id-type="pmid">23794184</pub-id>
        </element-citation>
      </ref>
      <ref id="ref14">
        <label>14</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cowie</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Management of skin toxicity related to the use of imatinib mesylate (STI571, Glivec trade mark) for advanced stage gastrointestinal stromal tumours</article-title>
          <source>Sarcoma</source>
          <year>2005</year>
          <volume>9</volume>
          <fpage>157</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">18521425</pub-id>
        </element-citation>
      </ref>
      <ref id="ref15">
        <label>15</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Le Nouail</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Viseux</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Chaby</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Billet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Denoeux</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Lok</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy</article-title>
          <source>Ann Dermatol Venereol</source>
          <year>2006</year>
          <volume>133</volume>
          <fpage>686</fpage>
          <lpage>688</lpage>
          <pub-id pub-id-type="pmid">17053739</pub-id>
        </element-citation>
      </ref>
      <ref id="ref16">
        <label>16</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Oosterom</surname>
              <given-names>AT</given-names>
              <suffix>van</suffix>
            </name>
            <name>
              <surname>Judson</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Verweij</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stroobants</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dumez</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sciot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Van Glabbeke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dimitrijevic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>OS</given-names>
            </name>
          </person-group>
          <article-title>Update of phase I study of imatinib (STI5721) in advanced soft tissue sarcoma and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group</article-title>
          <source>Eur J Cancer</source>
          <year>2002</year>
          <volume>38</volume>
          <fpage>83</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">11750844</pub-id>
        </element-citation>
      </ref>
      <ref id="ref17">
        <label>17</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Demetri</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>von Mehren</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Blanke</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Eisenberg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Heinrich</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Tuveson</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Janicek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Silverman</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Silberman</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Capdeville</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kiese</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dimitrijevic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Druker</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Corless</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Joensuu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>347</volume>
          <fpage>472</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="pmid">12181401</pub-id>
        </element-citation>
      </ref>
      <ref id="ref18">
        <label>18</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Verweij</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Oosterom</surname>
              <given-names>A</given-names>
              <suffix>van</suffix>
            </name>
            <name>
              <surname>Blay</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Judson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Rodenhuis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Radford</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Le Cesne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hogendoorn</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>di Paola</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>OS</given-names>
            </name>
          </person-group>
          <article-title>Imatinib mesylate (STI-571 Glivec&#xAE;, Gleevec&#x2122;) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study</article-title>
          <source>Eur J Cancer</source>
          <year>2003</year>
          <volume>39</volume>
          <fpage>2006</fpage>
          <lpage>2011</lpage>
          <pub-id pub-id-type="pmid">12957454</pub-id>
        </element-citation>
      </ref>
      <ref id="ref19">
        <label>19</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Verweij</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Casali</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Zalcberg</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Le Cesne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Reichardt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Blay</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Issels</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Oosterom</surname>
              <given-names>A</given-names>
              <suffix>van</suffix>
            </name>
            <name>
              <surname>Hogendoorn</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Van Glabbeke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bertulli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Judson</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>364</volume>
          <fpage>1127</fpage>
          <lpage>1134</lpage>
          <pub-id pub-id-type="pmid">15451219</pub-id>
        </element-citation>
      </ref>
      <ref id="ref20">
        <label>20</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Pietras</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>&#xD6;stman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sj&#xF6;quist</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Buchdunger</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Heldin</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors</article-title>
          <source>Cancer Res</source>
          <year>2001</year>
          <volume>61</volume>
          <fpage>2929</fpage>
          <lpage>2934</lpage>
          <pub-id pub-id-type="pmid">11306470</pub-id>
        </element-citation>
      </ref>
      <ref id="ref21">
        <label>21</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Ugurel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hildenbrand</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dippel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hochhaus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Dose-dependent severe cutaneous reactions to imatinib</article-title>
          <source>Br J Cancer</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>1157</fpage>
          <lpage>1159</lpage>
          <pub-id pub-id-type="pmid">12698177</pub-id>
        </element-citation>
      </ref>
      <ref id="ref22">
        <label>22</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Metcalfe</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Akin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dimitrijevic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Butterfield</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>McMahon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Longley</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>1741</fpage>
          <lpage>1744</lpage>
          <pub-id pub-id-type="pmid">11861291</pub-id>
        </element-citation>
      </ref>
      <ref id="ref23">
        <label>23</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Enoksson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lyberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>M&#xF6;ller-Westerberg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fallon</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lunderius-Andersson</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Mast cells as sensors of cell injury through IL-33 recognition</article-title>
          <source>J Immunol</source>
          <year>2011</year>
          <volume>186</volume>
          <fpage>2523</fpage>
          <lpage>2528</lpage>
          <pub-id pub-id-type="pmid">21239713</pub-id>
        </element-citation>
      </ref>
      <ref id="ref24">
        <label>24</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Dillon</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Sprecher</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hammond</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bilsborough</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rosenfeld-Franklin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Presnell</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Haugen</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Harder</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bort</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mudri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kuijper</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Bukowski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shea</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Dasovich</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Lockwood</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>LeCiel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Waggie</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Day</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Topouzis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kuestner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Parrish-Novak</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice</article-title>
          <source>Nat Immunol</source>
          <year>2004</year>
          <volume>5</volume>
          <fpage>752</fpage>
          <lpage>760</lpage>
          <pub-id pub-id-type="pmid">15184896</pub-id>
        </element-citation>
      </ref>
      <ref id="ref25">
        <label>25</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Steinhoff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bienenstock</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schmelz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wie</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Biro</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus</article-title>
          <source>J Invest Dermatol</source>
          <year>2006</year>
          <volume>126</volume>
          <fpage>1705</fpage>
          <lpage>1718</lpage>
          <pub-id pub-id-type="pmid">16845410</pub-id>
        </element-citation>
      </ref>
      <ref id="ref26">
        <label>26</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Mukhopadhyay</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Do</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Ong</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Khoo</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Masilamani</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Vincent</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>TT</given-names>
            </name>
          </person-group>
          <article-title>The role of stem cell factor and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role?</article-title>
          <source>Br J Dermatol</source>
          <year>2011</year>
          <volume>164</volume>
          <fpage>372</fpage>
          <lpage>386</lpage>
          <pub-id pub-id-type="pmid">20846303</pub-id>
        </element-citation>
      </ref>
      <ref id="ref27">
        <label>27</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Belleudi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cardinali</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Picardo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Torrisi</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>KGF promotes paracrine activation of the SCF/c-KIT axis from human keratinocytes to melanoma cells</article-title>
          <source>Transl Oncol</source>
          <year>2010</year>
          <volume>3</volume>
          <fpage>80</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">20360932</pub-id>
        </element-citation>
      </ref>
      <ref id="ref28">
        <label>28</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Gangemi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Allegra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Profita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saitta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gerace</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bonanno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alonci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Petrungaro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Musolino</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia</article-title>
          <source>Cancer Invest</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>212</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="pmid">23402297</pub-id>
        </element-citation>
      </ref>
      <ref id="ref29">
        <label>29</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Musolino</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Allegra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Profita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alonci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saitta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bonanno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Innao</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gangemi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease</article-title>
          <source>Br J Hematol</source>
          <year>2013</year>
          <volume>160</volume>
          <fpage>709</fpage>
          <lpage>710</lpage>
        </element-citation>
      </ref>
      <ref id="ref30">
        <label>30</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Musolino</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Allegra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Profita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alonci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saitta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Petrungaro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bonanno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gerace</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Calabr&#xF2;</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gangemi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Reduction in IL-33 plasma levels might be involved in T-cell dysregulation in chronic lymphocytic leukemia</article-title>
          <source>Acta Haematol</source>
          <year>2013</year>
          <volume>131</volume>
          <fpage>165</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">24217710</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
